Evaluating Mefloquine Dosage Effects and Tolerability in Artesunate-Mefloquine Regimens for MalariaMeta-analysis shows mefloquine dose impacts malaria recurrence in children

Malaria journal Published August 25, 2026 PubMed ↗ DOI ↗ Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Higher mefloquine doses reduce malaria recrudescence, but high rates of early vomiting in children aged 1-5 limit dose optimization.

This systematic review and individual patient data meta-analysis evaluated the efficacy and tolerability of artesunate-mefloquine (AS-MQ) regimens for treating uncomplicated falciparum malaria. The study included 6,761 patients across Asia, Africa, and South America to determine how varying mefloquine doses influence clinical outcomes, specifically focusing on recrudescence rates at 42 days.

The primary finding indicates that the AS-MQ regimen is highly effective in regions with low to moderate transmission where artemisinin resistance is not prevalent. In both Asia and Africa, PCR-corrected recrudescence rates were notably low, recorded at approximately 2.4% and 2.5% respectively. These figures suggest that the combination therapy provides a robust clinical response for patients across diverse geographical settings.

A critical component of the analysis was the dose-response relationship of mefloquine in Asian cohorts. The data demonstrated a significant dose-effect, where each 1 mg/kg increase in mefloquine resulted in a statistically significant reduction in recrudescence risk (AHR 0.89; 95% CI 0.83-0.96). This suggests that optimizing the dosage of mefloquine can directly improve the durability of the treatment's efficacy.

However, the clinical utility of higher doses is complicated by tolerability issues, particularly in pediatric populations. The study identified a significant trend regarding vomiting rates within one hour of dosing. Children between 1 and 5 years old experienced significantly higher rates of vomiting (3.4%) compared to children aged 5-11 years (1.7%) and patients over 12 years old (1.1%).

When comparing pediatric outcomes to adult cohorts, the results varied by region. In Asia, children under 5 years showed a significantly higher hazard of recrudescence compared to adults (HR 3.01; p < 0.001). Conversely, in Africa, no statistically significant difference was observed between these age groups (p = 0.133), highlighting the potential influence of local transmission dynamics or varying treatment protocols on clinical outcomes.

Clinicians must weigh the benefit of higher mefloquine doses against the risk of early-onset vomiting. While increasing the dose reduces the likelihood of malaria recurrence, the high incidence of immediate vomiting in very young children may limit the ability to optimize dosing for this specific demographic. This creates a practical challenge in clinical settings where maximizing efficacy is paramount. In conclusion, AS-MQ remains an effective treatment for uncomplicated falciparum malaria. While mefloquine dose optimization is a viable strategy to reduce recrudescence rates, clinicians must remain mindful of the age-specific tolerability profiles. The significant risk of early vomiting in children under 5 years old may necessitate careful management when attempting to maximize the therapeutic impact of mefloquine in pediatric patients.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in understanding the specific impact of mefloquine dosing on outcomes and tolerability in pediatric populations. While previous data confirmed that malaria vaccines like RTS,S/AS01 and R21/Matrix-M1 reduce risk in children, this study provides specific data on the pharmacodynamics of AS-MQ. It also complements evidence regarding regional variations in Africa, where some studies noted a 54.6% reduction in incidence with SP+AQ compared to SP alone.

Malaria remains a serious health concern for many families, particularly for young children in regions where the disease is common. For these children, getting the right treatment quickly is vital to ensure they recover fully and do not get sick again shortly after their initial treatment. This research looks at how specific combinations of medications can improve outcomes for those fighting malaria.

Researchers conducted a large-scale analysis involving 6,761 patients across Asia, Africa, and South America. The study focused on people with uncomplicated falciparum malaria, including children between the ages of one and five. They looked specifically at a treatment plan using two medicines: artesunate and mefloquine. The goal was to see how different amounts of mefloquine affected whether the malaria came back within 42 days of treatment.

The findings showed that the combination of artesunate and mefloquine is very effective at treating malaria in areas where drug resistance is not yet a major problem. In Asia, researchers found a clear link between the amount of mefloquine given and the risk of the disease returning; higher doses were linked to lower rates of recurrence. However, the study also highlighted a specific challenge for very young children. While these children are at a higher risk of malaria returning in some regions, they also experienced more frequent vomiting shortly after taking their medication compared to older children and adults.

Regarding safety, the main concern identified was vomiting within one hour of taking the medicine. This issue was most common in children aged one to five years. Because this side effect is linked to the amount of medicine given, it can make it difficult for doctors to find the perfect dose that provides the best protection while keeping the child comfortable. It is important to remember that this study is a meta-analysis, which means it combines data from many different sources to find broad trends. While it provides valuable information on how mefloquine works, it does not change immediate medical practices for every individual patient. Doctors will still make treatment decisions based on local guidelines and the specific needs of each child. For now, this research helps experts better understand how to balance effective treatment with manageable side effects for young children in malaria-prone areas.

What this means for you:

Higher mefloquine doses can reduce malaria recurrence, but may cause more vomiting in children under five years old.

Study Details

Study typeMeta analysis

Sample sizen = 6,761

EvidenceLevel 1

PublishedAug 2026

PMID42638106

View Original Abstract ↓

INTRODUCTION: A combination of mefloquine associated with artesunate (AS-MQ) was the first artemisinin-based combination therapy (ACT) to be used widely for acute uncomplicated P. falciparum malaria. METHODS: Individual patient data from 31 studies of patients with uncomplicated falciparum malaria treated with various AS-MQ regimens (target mefloquine dose 25 mg/kg), conducted in Asia, Africa and South America, were pooled and analysed to investigate the effects of MQ mg/kg dosing on malaria recurrence and other clinical, parasitological and tolerability endpoints. RESULTS: A total of 6,761 patients were enrolled in clinical studies conducted between 1995 and 2018; the majority (74%) were from Asia. The median age of study participants was 18 years (interquartile range IQR 8-30 years), of whom 13.5% (915/6761) were aged less than 5 years old. Participants received an estimated median [range] total mg/kg dose of mefloquine and artesunate of 25 [6.8-60] and 12 [3.6-33.3] respectively, and 1,572 (23.4%) participants were treated with the coformulation. The PCR-corrected recrudescence rate 42 days after any ASMQ treatment was 2.4% for patients enrolled in Asia and 2.5% in Africa, before artemisinin resistance emerged. Corresponding rates in children aged 1 to < 5 years were 2.9% and 3.3%. After adjusting for background artemisinin resistance, the hazard of recrudescence was higher in children aged 1 to < 5 years than in adults in Asia, but not in Africa (Asia, HR 3.01, 95%CI 1.60-5.64, p < 0.001; Africa HR 5.18, 95% CI 0.61-44.28, p = 0.133). There was only one recrudescent infection in South America. A significant MQ dose-effect was observed in Asia in patients treated with 3-dose regimens (AHR 0.89, 95% CI 0.83-0.96, p = 0.003 for 1 mg/kg increase in dose). Vomiting rates within an hour of dosing were highest in children 1- 5 years of age (n = 140) at 3.4% doses (13/378) compared to 1.7% (20/1,168) in children 5-11 years (n = 476), and 1.1% (47/4,191) in patients 12 years of age or older (n = 2027) (p < 0.001, test for trend). CONCLUSION: AS-MQ administered over three days is a highly efficacious ACT in low to moderate transmission areas without artemisinin resistance. While further optimisation of the mefloquine dose in the coformulation in children aged 1-5 years could be considered, dose-related early vomiting is highest in this age group and may preclude this.

Evaluating Mefloquine Dosage Effects and Tolerability in Artesunate-Mefloquine Regimens for MalariaMeta-analysis shows mefloquine dose impacts malaria recurrence in children

How this fits prior evidence

Study Details

High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants

High-Dose Vitamin D May Reduce BPD in Preterm Infants

Clinical research that matters. Delivered to your inbox.

Evaluating Mefloquine Dosage Effects and Tolerability in Artesunate-Mefloquine Regimens for MalariaMeta-analysis shows mefloquine dose impacts malaria recurrence in children

How this fits prior evidence

More on Malaria

Study Details

High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants

High-Dose Vitamin D May Reduce BPD in Preterm Infants

Clinical research that matters. Delivered to your inbox.

Related in Pediatrics

From Other Specialties